Is NMN legal in Europe? It is classified as a Novel Food — and as of 2026 still unauthorised, with EFSA opinions in and applications pending. The honest, source-cited answer for researchers.
The 2026 list names dozens of growth-hormone peptides as prohibited at all times for athletes. But the silences in Section S2 — BPC-157, TB-500, MOTS-c — matter as much as the named substances.
RUO is a labelling category about intended use, not a quality grade or a safety claim. It is legitimate for genuine laboratory science — and routinely abused by the grey market as a fig leaf. Here is what the label actually does, and what it cannot.
A research peptide sold across Europe, never approved as a medicine, and quietly governed by the question almost nobody asks correctly.
A neutral 2026 map of how the FDA, the EMA and the anti-doping world actually treat research peptides — and why “Research Use Only” is a defined legal frame, not a loophole.
On 1 June 2026 the European Medicines Agency published its first rulebook for manufacturing synthetic-peptide medicines. Here is what it actually says, what it does not touch, and why it quietly raises the quality bar for everyone.
A US advisory committee meets on 23–24 July 2026 to weigh whether a group of research peptides — including BPC-157 and TB-500 — should return to a category permitting regulated compounding. Here is what is actually being decided, and what it does not change.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.